DLX 0201
Alternative Names: DLX0201Latest Information Update: 16 Jul 2016
At a glance
- Originator DELEX Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Nausea and vomiting
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Nausea and vomiting in Canada
- 04 May 2005 DELEX Therapeutics has been acquired by YM BioSciences
- 27 Aug 2003 Preclinical trials in Emesis in Canada (unspecified route)